

Daiichi Sankyo Settled Patent Litigation for Evoxac[®]

Bio-Medicine.Org

PARSIPPANY, N.J., Aug. 4 /PRNewswire/ -- Daiichi Sankyo, Inc. and its parent company, Daiichi Sankyo Co., Ltd, (collectively, "Daiichi Sankyo") have reached an agreement with Apotex Inc. and Apotex Corp. (collectively, "Apotex") to settle their patent litigation involving Apotex's challenge to Daiichi Sankyo's U.S. Patent Number 5,340,821 (hereinafter referred to as "the '821 patent") covering Evoxac[®] (cevimeline HCl). Under the agreement, Apotex has received a license to the '821 patent that will permit Apotex to commercially launch its generic cevimeline HCl product in the fourth quarter of 2012.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com [1].

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please v
'/>"/>

[SOURCE](#) [2]

Source URL (retrieved on 01/29/2015 - 9:54pm):

<http://www.mdtmag.com/news/2010/08/daiichi-sankyo-settled-patent-litigation-evoxac%C3%A3%E2%80%9A%C2%AE>

Links:

[1] <http://www.daiichisankyo.com/>

[2] <http://www.bio-medicine.org/medicine-technology-1/Daiichi-Sankyo-Settled-Patent-Litigation-for-Evoxac-AE-10111-1/>